A new class of drugs, known as SGLT2 inhibitors, is increasingly being prescribed for the treatment of type 2 diabetes, but may increase the risk of rare but serious complication known as diabetic ketoacidosis. In a new study published in the New England Journal of Medicine, investigators from Brigham and Women’s Hospital quantify that risk, finding...